Anti-atherosclerotic action of vascular D1 receptors

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue SUPPL., 1999, Pages

  Yasunari, Kenichi ^a   Kohno, Masakazu ^a   Kano, Hiroaki ^a   Hanehira, Takao ^a   Minami, Mieko ^a   Yoshikawa, Junichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dopamine; Migration; Proliferation; Vascular smooth muscle

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; ADENYLATE CYCLASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE D; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; HYPERTROPHY; MOUSE; NONHUMAN; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTERIOSCLEROSIS; CELL DIVISION; CELL MOTION; DRUG EFFECT; REVIEW;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ARTERIOSCLEROSIS; CELL DIVISION; CELL MOVEMENT; DOPAMINE; DOPAMINE AGONISTS; HYPERTROPHY; ISOQUINOLINES; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, DOPAMINE D1; TETRAHYDROISOQUINOLINES;

EID: 0033049212     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Goldberg LI. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol. Rev. 1972; 24: 1-29.
2. Yasunari K, Kohno M, Balmforth AJ et al. Glucocorticoids and D1 receptors on vascular smooth muscle cells. Hypertension 1989; 13: 575-81.
3. 1 receptors on vascular smooth muscle. Am. J. Physiol. 1993; 264: F24-30.
4. 1 receptors on vascular smooth muscle cells are regulated by glucocorticoid and sodium chloride. Am. J. Physiol. 1994; 267: R628-34.
5. Stoof JC, Kebabian JW. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci. 1983; 35: 2281-96.
6. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 1993; 16: 299-321.
7. Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 1992; 13: 61-9.
8. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 1994; 15: 264-70.
9. Ozono R, O'Connell DP, Vaughan C. et al. Expression of the subtype IA dopamine receptor in the rat heart. Hypertension 1996; 27: 693-703.
10. 125I-Sch 23982. Am. J. Physiol. 1988; 255: F970-6.
11. 1A receptor protein in rat kidneys. Am. J. Physiol. 1995; 268: F1185-97.
12. Kopia GA, Valocik RE. Demonstration of specific D1 receptormediated coronary vasodilation in the anesthetized dog. J. Pharmacol. Exp. Ther. 1989; 248: 215-21.
13. 1A dopamine receptor in the pathogenesis of genetic hypertension. J. Clin. Invest. 1996; 97: 2283-8.
14. Abell TJ, Richard AM, Ikram H, Espiner EA, Yandle Y. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem. Biophys. Res. Commun. 1989; 160: 1392-6.
15. Nakai T, Nakayama M, Yamamoto S, Kato R. α1 -Adrenergic stimulation and β2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol. Pharmacol. 1989; 37: 30-6.
16. Yasunari K, Kohno M, Yokokawa K, Horio T, Kano H, Takeda T. Vascular D1 receptors. Hypertens. Res. 1995; 18 (Suppl. I): S29-33.
17. Ross R. The pathogenesis of atherosclerosisan update. N. Engl. J. Med. 1986; 314: 488-500.
18. Yasunari K, Kohno M, Hasuma T et al. Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3164-73.
19. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krehs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cell via signaling pathways that are distinct migration from proliferation. J. Clin. Invest. 1994; 93: 1266-74.
20. 45Ca fluxes in isolated smooth muscle cells. Am. J. Physiol. 1984; 246: C431-8.
21. Graf K, Xi X-P, Yang D, Fleck E, Hsuch WA, Law RE. Mitogenactivated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997; 29: 334-9.
22. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem. J. 1992; 288: 527-32.
23. 1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Atherosclerosis 1984; 53: 77-82.
24. Kano H, Kohno M, Yasunari K et al. Adrenomedullin as a novel antiproliferatieve factor of vascular smooth muscle cells. J. Hypertens. 1996; 14: 209-13.
25. Graves LM, Bornfeldt KE, Raines EW et al. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogenactivated protein kinase in human arterial smooth muscle cells. Proc. Natl Acad. Sci. USA 1993; 90: 10300-4.
26. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995; 9: 726-35.
27. Tsuda T, Kawahara Y, Ishida Y, Koide M, Shii K, Yokoyama M. Angiotensin II stimulates two myelin basic protein/microtubuleassociated protein 2 kinase in cultured vascular smooth muscle cells. Circ. Res. 1992; 71: 620-30.
28. Malarkey K, McLees A, Paul A, Gould GW, Plevin R. The role of protein kinase C in activation and termination of mitogen-activated protein kinase activity in angiotensin II-stimulated rat aortic smooth muscle cells. Cell Signal 1996; 8: 123-9.
29. Kribben A, Wieder DE, Li X et al. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am. J. Physiol. 1993; 265: C939-45.
30. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J. Biol. Chem 1993; 268: 7338-45.
31. Wu J, Dent P, Jelinek T, Wolfman A, Meber MJ, Sturgill TW. Inhibition of the HGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 1993; 262: 1065-9.
32. Cook SJ, McCormick F. Inhibition by cAMP of ras-dependent activation of Raf. Science 1993; 262: 1069-72.
33. Lassegue B, Alexander RW, Clark M, Akers M, Griendling KK. Phosphatidylcholine is a major source of phosphatidic acid and diacylglycerol in angiotensin II-stimulated vascular smooth muscle cells. Biochem. J. 1993; 292: 509-17.
34. Kondo T, Inui H, Konishi F, Inagami T. Phospholipase D mimics platelet-derived growth factor as a competence factor in vascular smooth muscle cells. J. Biol. Chem 1992; 267: 23609-16.
35. Valius M, Kazlauskas A. Phospholipase C-γl and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993; 73: 321-34.
36. Kim U-H, Kim JW, Ghee SG. Phosphorylation of phospholipase C-γ by cAMP-dependent protein kinase. J. Biol. Chem. 1989; 264: 20 167 70.
37. Yu P-Y, Asico LD, Eisner GM, Jose PA. Differential regulation of renal phospholipase C isoforms by catecholamines. J. Clin. Invest. 1995; 95: 304-8.
38. Wu L, Champlain J. Inhibition by cyclic AMP of basal and induced inositol phosphate production in cultured aortic smooth muscle cells from Wistar-Kyoto and spontaneously hypertensive rat. J. Hypertens. 1996; 14: 593-9.
39. mapk are required for fibrohlast proliferation. Proc. Natl Acad. Sci. USA 1993; 90: 8319-23.
40. Dzau VJ, Gibbons GH. Cell biology of vascular hypertrophy in systemic hypertension. Am. J. Cardiol. 1988; 62: G30-5.
41. Owens GK, Reidy M. Hyperplastic growth response of vascular smooth muscle cells following indication of acute hypertension in rats by aortic coarctation. Circ. Res. 1985; 57: 695-705.
42. Benem RD. An autoradiographic and pathologic study of cellular proliferation in rabbit arteries correlated with an increase in arterial pressure. Blood Vessels 1976; 13: 100-28.
43. Owens GK, Schwartz SM. Alteration in vascular smooth muscle mass in spontaneously hypertensive rat. Circ. Res. 1982; 51: 280-9.
44. Owens GK, Schwanz SM. Vascular smooth muscle cell hypertrophy and hyperploidy in the Goldblatt hypertensive rat. Circ. Res. 1983; 53: 491-501.
45. Ross R, Raines EW, Bowen-Dope DF. The biology of platelet-derived growth factor. Cell 1986; 46: 155-69.
46. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine D1-like receptor stimulation inhibits hypertrophy induced by platelet-derived growth factor in cultured rat renal vascular smooth muscle cells. Hypertension 1997; 29: 350-5.
47. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Aldose reductase inhibitor prevents hyperproliferalion and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Anterioscter. Thromb. Vasc. Biol. 1995; 15: 2207-12.
48. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentration. Hypertension 1996; 28: 159-68.
49. Goldstein DS. Plasma catecholamines and essential hypertension: An analytical review. Hypertension 1983; 5: 86-9.
50. Bühler HU, Prada MD, Haetely W, Picotti GB. Plasma adrenaline, noradrenaline and dopamine in man and different animal species. J. Physiol. 1978; 276: 311-20.
51. 2 stimulated mitogenesis of coronary artery smooth muscle cell involves activation of mitogen-activated protein kinase and S6 kinase. J. Biol. Chem. 1994; 269: 5693-8.
52. Working Group on Renovascular Hypertension. Detection evaluation and treatment of renovascular hypertension. Arch. Intern. Med. 1987; 147: 820-9.
53. Schwartz SM, DeBois D, O'Brien ERM. The intima: Soil for atherosclerosis and restenosis. Circ. Res. 1995; 77: 445-65.
54. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 1992; 70: 593-9.